New England Journal of Medicine, volume 382, issue 20, pages 1894-1905

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn ¹

Shukui Qin ¹

Masafumi Ikeda ¹

Peter R. Galle ¹

Michel Ducreux ¹

Tae-You Kim ¹

Masatoshi Kudo ¹

Valeriy Breder ¹

Philippe Merle ¹

Ahmed O. Kaseb ¹

Daneng Li ¹

Wendy Verret ¹

Derek-Zhen Xu ¹

Sairy Hernandez ¹

Juan Liu ¹

Chen Huang ¹

Sohail Mulla ¹

Yulei Wang ¹

Ho-Yeong Lim ¹

Andrew X. Zhu ¹

Ann-Lii Cheng ¹

Show full list: 21 authors

Hide authors affiliations Show authors affiliations: 1 affiliation

From the Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles (R.S.F.), the City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte (D.L.), and Genentech, South San Francisco (W.V., S.H., Y.W.) — all in California; the People’s Liberation Army Cancer Center, Jinling Hospital, Nanjing (S.Q.), and Roche Product Development (D.-Z.X., J.L., C.H.) and Jiahui International Cancer Center, Jiahui Health (A.X.Z.), Shanghai — all in China; National Cancer...

Jonsson Comprehensive Cancer Center

City of Hope National Medical Center

Publication type: Journal Article

Publication date: 2020-05-13

Massachusetts Medical Society

Journal: New England Journal of Medicine

scimago Q1

SJR: 20.544

CiteScore: 145.4

Impact factor: 96.2

ISSN: 00284793, 15334406

DOI: 10.1056/NEJMoa1915745

Copy DOI

PubMed ID: 32402160

General Medicine

Abstract

Background The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinom...

Found

Top-30

Journals

	50 100 150 200 250 300 350
Cancers	Cancers, 326, 6.83% Cancers 326 publications, 6.83%
Frontiers in Oncology	Frontiers in Oncology, 161, 3.37% Frontiers in Oncology 161 publications, 3.37%
Frontiers in Immunology	Frontiers in Immunology, 156, 3.27% Frontiers in Immunology 156 publications, 3.27%
Journal of Hepatocellular Carcinoma	Journal of Hepatocellular Carcinoma, 136, 2.85% Journal of Hepatocellular Carcinoma 136 publications, 2.85%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 87, 1.82% International Journal of Molecular Sciences 87 publications, 1.82%
Liver Cancer	Liver Cancer, 81, 1.7% Liver Cancer 81 publications, 1.7%
Journal of Hepatology	Journal of Hepatology, 62, 1.3% Journal of Hepatology 62 publications, 1.3%
Hepatology Research	Hepatology Research, 62, 1.3% Hepatology Research 62 publications, 1.3%
Hepatology	Hepatology, 54, 1.13% Hepatology 54 publications, 1.13%
Liver International	Liver International, 51, 1.07% Liver International 51 publications, 1.07%
Cancer Medicine	Cancer Medicine, 48, 1.01% Cancer Medicine 48 publications, 1.01%
JHEP Reports	JHEP Reports, 44, 0.92% JHEP Reports 44 publications, 0.92%
Journal for ImmunoTherapy of Cancer	Journal for ImmunoTherapy of Cancer, 44, 0.92% Journal for ImmunoTherapy of Cancer 44 publications, 0.92%
Scientific Reports	Scientific Reports, 40, 0.84% Scientific Reports 40 publications, 0.84%
BMC Cancer	BMC Cancer, 39, 0.82% BMC Cancer 39 publications, 0.82%
Journal of Cancer Research and Clinical Oncology	Journal of Cancer Research and Clinical Oncology, 39, 0.82% Journal of Cancer Research and Clinical Oncology 39 publications, 0.82%
World Journal of Gastroenterology	World Journal of Gastroenterology, 39, 0.82% World Journal of Gastroenterology 39 publications, 0.82%
Clinical Cancer Research	Clinical Cancer Research, 38, 0.8% Clinical Cancer Research 38 publications, 0.8%
Frontiers in Pharmacology	Frontiers in Pharmacology, 35, 0.73% Frontiers in Pharmacology 35 publications, 0.73%
Hepatology International	Hepatology International, 33, 0.69% Hepatology International 33 publications, 0.69%
HepatoBiliary Surgery and Nutrition	HepatoBiliary Surgery and Nutrition, 33, 0.69% HepatoBiliary Surgery and Nutrition 33 publications, 0.69%
World Journal of Gastrointestinal Oncology	World Journal of Gastrointestinal Oncology, 32, 0.67% World Journal of Gastrointestinal Oncology 32 publications, 0.67%
Therapeutic Advances in Medical Oncology	Therapeutic Advances in Medical Oncology, 31, 0.65% Therapeutic Advances in Medical Oncology 31 publications, 0.65%
Current Oncology	Current Oncology, 29, 0.61% Current Oncology 29 publications, 0.61%
International Immunopharmacology	International Immunopharmacology, 29, 0.61% International Immunopharmacology 29 publications, 0.61%
Clinical Journal of Gastroenterology	Clinical Journal of Gastroenterology, 28, 0.59% Clinical Journal of Gastroenterology 28 publications, 0.59%
Future Oncology	Future Oncology, 28, 0.59% Future Oncology 28 publications, 0.59%
Oncology	Oncology, 26, 0.54% Oncology 26 publications, 0.54%
Journal of Clinical Medicine	Journal of Clinical Medicine, 24, 0.5% Journal of Clinical Medicine 24 publications, 0.5%
	50 100 150 200 250 300 350

Publishers

	100 200 300 400 500 600 700 800 900
Springer Nature	Springer Nature, 831, 17.4% Springer Nature 831 publications, 17.4%
Elsevier	Elsevier, 803, 16.81% Elsevier 803 publications, 16.81%
MDPI	MDPI, 595, 12.46% MDPI 595 publications, 12.46%
Wiley	Wiley, 467, 9.78% Wiley 467 publications, 9.78%
Frontiers Media S.A.	Frontiers Media S.A., 409, 8.56% Frontiers Media S.A. 409 publications, 8.56%
Taylor & Francis	Taylor & Francis, 341, 7.14% Taylor & Francis 341 publications, 7.14%
S. Karger AG	S. Karger AG, 122, 2.55% S. Karger AG 122 publications, 2.55%
Baishideng Publishing Group	Baishideng Publishing Group, 106, 2.22% Baishideng Publishing Group 106 publications, 2.22%
BMJ	BMJ, 94, 1.97% BMJ 94 publications, 1.97%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 88, 1.84% Ovid Technologies (Wolters Kluwer Health) 88 publications, 1.84%
SAGE	SAGE, 76, 1.59% SAGE 76 publications, 1.59%
AME Publishing Company	AME Publishing Company, 73, 1.53% AME Publishing Company 73 publications, 1.53%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 61, 1.28% American Association for Cancer Research (AACR) 61 publications, 1.28%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 60, 1.26% Georg Thieme Verlag KG 60 publications, 1.26%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 44, 0.92% American Society of Clinical Oncology (ASCO) 44 publications, 0.92%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 42, 0.88% Cold Spring Harbor Laboratory 42 publications, 0.88%
Oxford University Press	Oxford University Press, 38, 0.8% Oxford University Press 38 publications, 0.8%
OAE Publishing Inc.	OAE Publishing Inc., 36, 0.75% OAE Publishing Inc. 36 publications, 0.75%
American Medical Association (AMA)	American Medical Association (AMA), 31, 0.65% American Medical Association (AMA) 31 publications, 0.65%
Spandidos Publications	Spandidos Publications, 25, 0.52% Spandidos Publications 25 publications, 0.52%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 20, 0.42% Public Library of Science (PLoS) 20 publications, 0.42%
Japan Society of Hepatology	Japan Society of Hepatology, 20, 0.42% Japan Society of Hepatology 20 publications, 0.42%
Research Square Platform LLC	Research Square Platform LLC, 20, 0.42% Research Square Platform LLC 20 publications, 0.42%
Hindawi Limited	Hindawi Limited, 18, 0.38% Hindawi Limited 18 publications, 0.38%
Japanese Society of Internal Medicine	Japanese Society of Internal Medicine, 16, 0.34% Japanese Society of Internal Medicine 16 publications, 0.34%
American Chemical Society (ACS)	American Chemical Society (ACS), 13, 0.27% American Chemical Society (ACS) 13 publications, 0.27%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 12, 0.25% American Association for the Advancement of Science (AAAS) 12 publications, 0.25%
Hans Publishers	Hans Publishers, 12, 0.25% Hans Publishers 12 publications, 0.25%
Society for Translational Oncology	Society for Translational Oncology, 11, 0.23% Society for Translational Oncology 11 publications, 0.23%
	100 200 300 400 500 600 700 800 900

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

5.4k

CITATIONS

5.4k Total citations

2.9k Recent citations

1390 Field Citation Ratio

249 Relative Citation Ratio

Cite this

GOST |

Cite this

GOST Copy

Finn R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma // New England Journal of Medicine. 2020. Vol. 382. No. 20. pp. 1894-1905.

GOST all authors (up to 50) Copy

Finn R. S., Qin S., Ikeda M., Galle P. R., Ducreux M., Kim T., Kudo M., Breder V., Merle P., Kaseb A. O., Li D., Verret W., Xu D., Hernandez S., Liu J., Huang C., Mulla S., Wang Y., Lim H., Zhu A. X., Cheng A. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma // New England Journal of Medicine. 2020. Vol. 382. No. 20. pp. 1894-1905.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1056/NEJMoa1915745

UR - https://doi.org/10.1056/NEJMoa1915745

TI - Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

T2 - New England Journal of Medicine

AU - Finn, Richard S.

AU - Qin, Shukui

AU - Ikeda, Masafumi

AU - Galle, Peter R.

AU - Ducreux, Michel

AU - Kim, Tae-You

AU - Kudo, Masatoshi

AU - Breder, Valeriy

AU - Merle, Philippe

AU - Kaseb, Ahmed O.

AU - Li, Daneng

AU - Verret, Wendy

AU - Xu, Derek-Zhen

AU - Hernandez, Sairy

AU - Liu, Juan

AU - Huang, Chen

AU - Mulla, Sohail

AU - Wang, Yulei

AU - Lim, Ho-Yeong

AU - Zhu, Andrew X.

AU - Cheng, Ann-Lii

PY - 2020

DA - 2020/05/13

PB - Massachusetts Medical Society

SP - 1894-1905

IS - 20

VL - 382

PMID - 32402160

SN - 0028-4793

SN - 1533-4406

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Finn,

author = {Richard S. Finn and Shukui Qin and Masafumi Ikeda and Peter R. Galle and Michel Ducreux and Tae-You Kim and Masatoshi Kudo and Valeriy Breder and Philippe Merle and Ahmed O. Kaseb and Daneng Li and Wendy Verret and Derek-Zhen Xu and Sairy Hernandez and Juan Liu and Chen Huang and Sohail Mulla and Yulei Wang and Ho-Yeong Lim and Andrew X. Zhu and Ann-Lii Cheng},

title = {Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma},

journal = {New England Journal of Medicine},

year = {2020},

volume = {382},

publisher = {Massachusetts Medical Society},

month = {may},

url = {https://doi.org/10.1056/NEJMoa1915745},

number = {20},

pages = {1894--1905},

doi = {10.1056/NEJMoa1915745}

}

MLA

Cite this

MLA Copy

Finn, Richard S., et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” New England Journal of Medicine, vol. 382, no. 20, May. 2020, pp. 1894-1905. https://doi.org/10.1056/NEJMoa1915745.

Found error?

Message

Support chat

Publisher

Massachusetts Medical Society

Journal

New England Journal of Medicine

scimago Q1

SJR

20.544

CiteScore

145.4

Impact factor

96.2

ISSN

00284793

15334406